Neuroprotective effects of topical CB1 agonist WIN 55212-2 on retinal ganglion cells after acute rise in intraocular pressure induced ischemia in rat

Experimental Eye Research

Volumn 110, Issue , 2013, Pages 55-58

  Pinar Sueiro, Sergio ^a,b,c   Zorrilla Hurtado, José Ángel ^a   Veiga Crespo, Patricia ^a   Sharma, Sansar C ^d,e   Vecino, Elena ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c Instituto Oftalmológico Bilbao IOB   (Spain)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

Acute ischemia; AM 251; Cannabinoids; CB1 receptor; Eye drops; Ischemia reperfusion model; Neuroprotection; WIN 55212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; TRANSCRIPTION FACTOR POU4F1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CELL COUNT; CELL DENSITY; CONTROLLED STUDY; FEMALE; INTRAOCULAR PRESSURE; MOSAICISM; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REPERFUSION INJURY; RETINA GANGLION CELL; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ANIMALS; BENZOXAZINES; CELL COUNT; DISEASE MODELS, ANIMAL; FEMALE; INTRAOCULAR PRESSURE; MORPHOLINES; NAPHTHALENES; NEUROPROTECTIVE AGENTS; OCULAR HYPERTENSION; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; REPERFUSION INJURY; RETINAL DISEASES; RETINAL GANGLION CELLS; TONOMETRY, OCULAR;

EID: 84875653203     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.02.009     Document Type: Article

References (32)

1. Agudo M., Pérez-Marín M.C., Sobrado-Calvo P., Lönngren U., Salinas-Navarro M., Cánovas I., Nadal-Nicolás F.M., Miralles-Imperial J., Hallböök F., Vidal-Sanz M. Immediate up regulation of proteins belonging to different branches of the apoptotic cascade in the retina after optic nerve transection and optic nerve crush. Invest. Ophthalmol. Vis. Sci. 2009, 50(1):424-431.
2. Ben Simon G.J., Hovda D.A., Harris N.G., Gomez-Pinilla F., Goldberg R.A. Traumatic brain injury induced neuroprotection of retinal ganglion cells to optic nerve crush. J. Neurotrauma 2006, 23:1072-1082.
3. Bessero A.C., Clarke P.G. Neuroprotection for optic nerve disorders. Curr. Opin. Neurol. 2010, 23:10-15.
4. Cabral G.A., Raborn E.S., Griffin L., Dennis J., Marciano-Cabral F. CB2 receptors in the brain: role in central immune function. Br. J. Pharmacol. 2008, 153:240-251.
5. Chien F.Y., Wang R.F., Mittag T.W., Podos S.M. Effect of WIN 55212-2, a cannabinoid receptor agonist on aqueous humor dynamics in monkeys. Arch. Ophthalmol. 2003, 121:87-90.
6. Crandall J., Matragoon S., Khalifa Y.M., Borlongan C., Tsai N.T., Caldwell R.B., Lion G.I. Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma. Ophthalmic Res. 2007, 39:69-75.
7. Croxford J.L., Pryce G., Jackson S.J., Ledent C., Giovannoni G., Pertwee R.G., Yamamura T., Baker D. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J. Neuroimmunol. 2008, 193:120-129.
8. de Lago E., Fernández-Ruíz J. Cannabinoids and neuroprotection in motor-related disorders. CNS. Neurol. Disord. Drug Targets 2007, 6:337-387.
9. El Remessy A.B., Khalil I.E., Matragoon S., Abou-Mohamed G., Tsai N.J., Roon P., Caldwell R.B., Caldwell R.W., Green K., Lion G.I. Neuroprotective effect of delta(9)-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am. J. Pathol. 2003, 163:1997-2008.
10. Feigenbaum J.J., Bergmann F., Richmond S.A., Mechoulam R., Nadler Y., Kloog Y., Sokolovsky M. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:9584-9587.
11. Fernández-López D., Martínez-Orgado J., Nuñez E., Romero J., Lorenzo P., Moro M.A., Lizasoain I. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212-2 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr. Res. 2006, 60:169-173.
12. Hare W.A., Wheeler L. Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine. Invest. Ophthalmol. Vis. Sci. 2009, 50(6):2940-2948.
13. Hepler R.S., Frank I.R. Marihuana smoking and intraocular pressure. JAMA 1971, 217:1392.
14. Howlett A.C. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. 2002, 68-69:619-631.
15. Johns D.R., Colby K.A. Treatment of Leber's hereditary optic neuropathy: theory to practice. Semin Opthalmol. 2002, 17:33-38.
16. Ju W.K., Kim K.Y., Hofmann H.D., Kim I.B., Lee M.Y., Oh S.J., Chun M.H. Selective neuronal survival and upregulation of PCNA in the rat inner retina following transient ischemia. J. Neuropathol. Exp. Neurol. 2000, 59(3):241-250.
17. Mechoulam R., Shohami E. Endocannabinoids and traumatic brain injury. Mol. Neurobiol. 2007, 36:68-77.
18. Nucci C., Gasperi V., Tartaglione R., Cerulli A., Terrioni A., Bari M., De Simone C., Agrò A.F., Morrone L.A., Corasaniti M.T., Bagetta G., Maccarrone M. Involvement of the endocannabinoid system in retinal damage after high intracellular pressure-induced ischemia in rats. Invest. Ophthalmol. Vis. Sci. 2007, 48:2997-3004.
19. Opere C.A., Zheng W.D., Zhao M., Lee J.S., Kulkarni K.H., Ohia S.E. Inhibition of potassium- and ischemia-evoked [3H] D-aspartate release from isolated bovine retina by cannabinoids. Curr. Eye Res. 2006, 31:645-653.
20. Pinar-Sueiro S., Martínez-Fernández R., Lage-Medina S., Aldamiz Echevarria L., Vecino E. Optic neuropathy in methylmalonic academia: the role of neuroprotection. J. Inherit. Metab. Dis. 2010, (Epub ahead of print). 10.1007/s10545-010-9084-8.
21. Porcella A., Maxia C., Gessa G.L., Pani L. The synthetic cannabinoid WIN 55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 2001, 13:409-412.
22. Rosenbaum D.M., Rosenbaum R.S., Gupta H., Singh M., Aggarwal A., Hall D.H., Roth S., Kessler J.A. The role of the p53 protein in the selective vulnerability of the inner retina to transient ischemia. Invest. Ophthalmol. Vis. Sci. 1998, 39:2132-2139.
23. Sánchez-Migallón M.C., Nadal-Nicolás F.M., Jiménez-López M., Sobrado-Calvo P., Vidal-Sanz M., Agudo-Barriuso M. Brain derived neurotrophic factor maintains Brn3a expression in axotomized rat retinal ganglion cells. Exp. Eye Res. 2011, 92(4):260-267.
24. Seki M., Lipton S.A. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma. Prog. Brain Res. 2008, 173:495-510.
25. Straiker A.J., Maguire G., Mackie K., Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest. Ophthalmol. Vis. Sci. 1999, 40:2442-2448.
26. Urcola J.H., Hernández M., Vecino E. Three experimental glaucoma models in rats: comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp. Eye Res. 2006, 83:429-437.
27. Van der Stelt M., Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med. 2005, 7:37-50.
28. Verma D. Pathogenesis of diabetic retinopathy - the missing link?. Med. Hypotheses 1993, 41:205-210.
29. Wheeler L.A., Gil D.W., WoldeMussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv. Ophthalmol. 2001, 45:290-296.
30. Wilhelm B., Lüdtke H., Wilhelm H., BRAION Study Group Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch. Clin. Exp. Ophthalmol. 2006, 244:551-558.
31. Yoles E., Belkin M., Schwartz M. HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J. Neurotrauma 1996, 13:49-57.
32. Yuan L., Neufeld A.H. Tumor necrosis factor-alpha: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia 2000, 32:42-50.